Wall Street analysts predict that U.S. Physical Therapy, Inc. (NYSE:USPH) will post sales of $112.28 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for U.S. Physical Therapy’s earnings, with the lowest sales estimate coming in at $112.11 million and the highest estimate coming in at $112.45 million. U.S. Physical Therapy reported sales of $103.03 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The firm is scheduled to report its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that U.S. Physical Therapy will report full-year sales of $452.10 million for the current financial year, with estimates ranging from $452.09 million to $452.11 million. For the next year, analysts expect that the firm will post sales of $478.82 million per share, with estimates ranging from $471.32 million to $486.31 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover U.S. Physical Therapy.

U.S. Physical Therapy (NYSE:USPH) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.05. The firm had revenue of $115.10 million for the quarter, compared to analyst estimates of $111.77 million. U.S. Physical Therapy had a net margin of 5.03% and a return on equity of 13.81%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 EPS.

Several research analysts have recently commented on the stock. Barrington Research restated a “hold” rating on shares of U.S. Physical Therapy in a research note on Friday, August 3rd. Jefferies Financial Group restated a “hold” rating and set a $105.00 price target on shares of U.S. Physical Therapy in a research note on Friday, August 3rd. Zacks Investment Research upgraded shares of U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Tuesday, August 7th. ValuEngine upgraded shares of U.S. Physical Therapy from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 26th. Finally, Sidoti lowered shares of U.S. Physical Therapy from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 25th. Five research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. U.S. Physical Therapy currently has an average rating of “Hold” and a consensus price target of $99.50.

U.S. Physical Therapy stock opened at $114.25 on Friday. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 56.15, a P/E/G ratio of 3.96 and a beta of 1.09. The company has a current ratio of 2.06, a quick ratio of 2.06 and a debt-to-equity ratio of 0.27. U.S. Physical Therapy has a twelve month low of $56.50 and a twelve month high of $118.75.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 7th. Stockholders of record on Tuesday, August 14th will be paid a dividend of $0.23 per share. The ex-dividend date of this dividend is Monday, August 13th. This represents a $0.92 annualized dividend and a dividend yield of 0.81%. U.S. Physical Therapy’s dividend payout ratio (DPR) is 44.23%.

In related news, COO Glenn Mcdowell sold 6,204 shares of the company’s stock in a transaction on Friday, August 3rd. The shares were sold at an average price of $114.81, for a total transaction of $712,281.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Lawrance W. Mcafee sold 3,100 shares of the company’s stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $115.59, for a total transaction of $358,329.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,304 shares of company stock worth $2,687,237. 2.50% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new stake in shares of U.S. Physical Therapy during the 2nd quarter worth $106,000. Stratos Wealth Partners LTD. bought a new stake in shares of U.S. Physical Therapy during the 1st quarter worth $109,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of U.S. Physical Therapy during the 2nd quarter worth $219,000. Itau Unibanco Holding S.A. bought a new stake in shares of U.S. Physical Therapy during the 2nd quarter worth $235,000. Finally, Atria Investments LLC bought a new stake in shares of U.S. Physical Therapy during the 1st quarter worth $207,000. 96.89% of the stock is owned by institutional investors and hedge funds.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Further Reading: Technical Analysis

Get a free copy of the Zacks research report on U.S. Physical Therapy (USPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.